Urolithin A is a gut-microbiome-derived metabolite of ellagitannins and ellagic acid from foods such as pomegranates, walnuts and berries. Because natural conversion varies substantially between people, direct Urolithin A supplementation bypasses the need for a specific urolithin-producing microbiome. Its best-established biological mechanism is mitophagy: selective recycling of damaged mitochondria. The evidence base now spans the landmark 2016 mechanistic work, human pharmacokinetic and safety studies, randomized trials in older adults, middle-aged adults and athletes, a randomized immune-aging trial, independent systematic reviews and meta-analysis, plus extensive preclinical work in muscle, osteoarthritis, brain aging and inter-organelle mitochondrial signaling. Human evidence is strongest for target engagement and selected muscle/mitochondrial outcomes. It does not yet establish prevention of age-related disease or extension of human lifespan.
First-in-human randomised trial establishing safety, bioavailability, and biomarker effects (not muscle-function outcomes) of urolithin A in elderly adults. Placed at Tier 2 — a genuine human RCT, but its primary purpose was safety/PK, with molecular biomarker changes as secondary outcomes rather than a functional or clinical endpoint.
Narrative (non-systematic) review of urolithin A's preclinical and clinical evidence base, written predominantly by authors affiliated with the compound's commercial manufacturer. Placed at Tier 2 for the synthesis value it provides, with the sponsor-affiliation caveat weighed heavily in how it should be read.
Randomised, double-blind, placebo-controlled proof-of-concept trial (ATLAS, NCT03464500) with a well-defined primary endpoint that was NOT met (peak power output), alongside statistically significant secondary findings (leg muscle strength). Placed at Tier 2: a genuine, reasonably well-conducted human RCT, but with a missed primary endpoint and sponsor-run design that argue against Tier 1 despite the positive secondary findings.
Double-blind, placebo-controlled randomised trial in a specific, high-performing athletic population. Placed at Tier 2 — a genuine RCT with useful negative and mixed findings, more independently led than the earlier Amazentis-run trials, but small, short, and in a narrow elite-athlete population.
Sourcedoi:10.1007/s40279-025-02292-5PMID 40839339PMC12628386
Blinded analytical study using a purpose-developed and validated HPLC coupled to triple-quadrupole mass spectrometry method, with recovery, precision, accuracy and matrix-effect validation reported, and independent academic authorship with a declared absence of competing interests. Strong within its scope — label accuracy for a snapshot of products — and silent on efficacy.
